The Government of Canada announced Monday (March 24, 2025) that it will work with OmniaBio to expand its facility at McMaster Innovation Park. This expansion aims to manufacture cell and gene therapies and provide production services to companies globally, strengthening Canada’s participation in global value chains. Cell and gene therapies have the potential to revolutionize the treatment of a broad range of life-threatening diseases.
“OmniaBio’s project has the potential to make the next generation of medicines in Canada for use in critical areas such as chronic diseases,” said Anita Anand, Minister of Innovation, Science and Industry. “The project will enhance the country’s innovation ecosystem and has the potential to attract world-leading investment to Canada, contributing to keeping the population safe and healthy.”
OmniaBio’s project will focus on advanced treatments for chronic diseases, including cancer, autoimmune conditions, diabetes, cardiovascular, and neurological diseases.
“Patient access to cell-based cancer therapies has been hindered by high manufacturing costs and complex cold-chain logistics,” said Mitchel Sivilotti, President and CEO, OmniaBio Inc. “OmniaBio will complete the transformation of our Hamilton facility into the first cell therapy Intelligent Factory, answering a Canadian and global call for innovation in the production and supply of biomedicines.”
OmniaBio’s expanded facility seeks to increase manufacturing efficiency fivefold while reducing production and supply costs by up to 50 percent, facilitating patient access to life-saving treatments for chronic diseases, including cancer.
Read the official announcement here.